Published on 24 Jan 2024 on Exec Edge via Yahoo Finance
By Daniella Parra
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) said it showed additional safety and tolerability data, marking the second positive Phase 3 study assessing TNX-102 SL for fibromyalgia management.